Global Migraine Drugs Market - 2024-2031

Global Migraine Drugs Market - 2024-2031

The global migraine drugs market reached US$ 10.90 billion in 2023 and is expected to reach US$ 23.70 billion by 2031, growing at a CAGR of 10.3% during the forecast period 2024-2031.

Migraine is a headache characterized by recurrent attacks of moderate to severe throbbing and pulsating pain on one side of the head. These attacks are caused by nerve fiber activation within brain blood vessels traveling inside the meninges. Untreated attacks can last from 4 to 72 hours. Common symptoms include increased sensitivity to light, noise, and odors, nausea, and vomiting. Migraines are most common in the morning, especially upon waking, and can occur before menstruation or after a stressful week.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Migraine

Migraine, a common neurological disorder, is gaining popularity due to factors like stressful lifestyles, poor diets, and environmental changes. This has led to an increased demand for effective treatments, particularly for frequent or chronic migraines. Pharmaceutical companies have developed innovative treatments like Calcitonin Gene-Related Peptide (CGRP) inhibitors, targeting the biological pathways involved in migraines.

The increased diagnosis of migraines, facilitated by better awareness and improved healthcare access, strengthens the market's potential. Research and development efforts focus on novel drug classes and personalized treatment approaches.

The increasing burden of migraines also drives demand for over-the-counter options like NSAIDs and prescription medications, contributing to the sustained growth of the migraine drugs market globally.For instance, according to article published in NCBI, migraine, a common neurologic disorder affecting over one billion people globally, is particularly prevalent in young adults and females. It is linked to various comorbidities like stress, sleep disturbances, and suicide.

The complex mechanisms of migraine development suggest various risk factors, including hormonal imbalances, genetic and epigenetic influences, cardiovascular, neurological, and autoimmune diseases.

High costs of Migraine Drugs

Migraine drug prices vary significantly, with over-the-counter options like Excedrin and Advil Migraine being affordable for episodic migraine relief. Chronic migraines require prescription medications like triptans, CGRP antagonists, and CGRP monoclonal antibodies, which are more expensive. These treatments, ranging from $10 for sumatriptan to over $1,000 for eptinezumab, reflect a growing market need for effective, long-term migraine management solutions, despite their high costs.

Segment Analysis

The global migraine drugs market is segmented based on drug class, route of administration, age group, distribution channel and region.

Drug Class:

NSAIDs segment is expected to dominate the migraine drugs market share

The NSAIDs segment are expected to hold a major portion of the migraine drugs market share. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a popular over-the-counter (OTC) treatment for migraines, often used as first-line treatments due to their affordability and effectiveness in managing mild to moderate migraines. These drugs, like ibuprofen, aspirin, and naproxen, reduce inflammation and alleviate pain, making them a popular choice for immediate symptom relief.

However, long-term use can lead to gastrointestinal side effects, prompting some patients to seek alternative treatments like triptans or CGRP inhibitors. Despite the growing demand for migraine-specific medications, NSAIDs remain a cornerstone of migraine management, particularly for those seeking rapid, non-prescription options.

Research indicates that NSAIDs provide a modest but significant benefit compared to placebos. However, in studies comparing NSAIDs with triptans, the former has performed nearly as well. NSAIDs are more effective when taken early in a migraine attack or soon after symptoms onset. Prescription NSAIDs have higher doses, but over-the-counter versions can also provide symptom relief.

CGRP Monoclonal Antibodies segment is the fastest-growing segment in the migraine drugs market share

The CGRP monoclonal antibodies segment is the fastest-growing segment in the migraine drugs market share and is expected to hold the market share over the forecast period.

CGRP monoclonal antibodies are transforming the migraine drugs market by offering a targeted, preventative treatment for migraine sufferers. They block the CGRP pathway, a critical component in migraine pain transmission, reducing the frequency and severity of attacks. This approach is particularly beneficial for chronic migraine patients. As these therapies offer lasting relief and fewer side effects, demand for CGRP monoclonal antibodies is driving growth in the migraine drugs market, potentially reshaping migraine management by focusing on long-term prevention rather than episodic treatment.

For instance, in July 2024, Teva has announced positive results from its Phase 3 SPACE study evaluating fremanezumab for pediatric migraine prevention. The study, the first to demonstrate the safety and efficacy of an anti-CGRP monoclonal antibody for pediatric migraine, met its primary endpoint by significantly reducing monthly migraine days compared to placebo. The safety profile observed was consistent with adult studies, and no new safety signals were identified.

Route of Administration:

Oral segment is expected to dominate the migraine drugs smarket share

The oral segment holds a major portion of the migraine drugs market share and is expected to continue to hold a significant portion of the migraine drugs market share during the forecast period due to the easy availability and convenience of oral medication in patients has been the major factor which leads to their even more the ease of patients who prefer this mode of treatment. Many patients are able to have their symptoms managed with the use of oral medications and this includes relief from pain, nausea and other related symptoms. There are different classes of oral medications that range from general drugs like ibuprofen or paracetamol to specific triptan medications to prevent migraines and even beta blockers or antiepileptics for migraines.

For instance, in Febraury 2023, Rimegepant (Nurtec) and ubrogepant (Ubrelvy) have been approved for the treatment of migraines with or without aura in patients aged 18 years and older. These medications act as antagonists to the CGRP receptor, which is involved in the innervation of the head-neck region, in an effort to counter these attacks.

Injectable segment is the fastest-growing segment in the migraine drugs market share

The injectable segment is the fastest-growing segment in the migraine drugs market share and is expected to hold the market share over the forecast period. Injectable medications for migraine attacks are quickly gaining fame owing to their mode of action and rapid efficacy which makes them the drug of choice among patients in case of severe or acute migraine attacks. Further, this is a treatment that can be safely applied which is useful especially to those patients who cannot take pills due to difficulty in swallowing or when there is nausea or vomiting associated with the attack. These benefits will encourage many practitioners to place this drug to various patients hence the increase in its prescription rate during the above mentioned period.

For instance, the drugs suffuse Sumatriptan injection are readily available to the patients for the quick relief of any migraine or cluster headache bouts that the patients may suffer as it is the most effective option for patients who have a problem in taking pills and can work within ten minutes of admittance. Therefore, thanks to high safety and efficiency level in the use of injectables, the technique is embraced in the global market and this makes the growth of the segment.

Geographical Analysis

North America is expected to hold a significant position in the migraine drugs market share

North America is expected to hold a significant position in the global Migraine Drugs market during the forecast period due to the novel drugs launches, FDA approvals, expansions, high prevalence of migraine cases in the region.

Moreover, migraines are becoming more prevalent due to increased awareness and healthcare initiatives. The availability of advanced healthcare infrastructure and specialized treatments like CGRP inhibitors are driving market growth.

Additionally, US-based pharmaceutical companies' strong R&D activities are introducing novel, more effective drugs, fuelling market growth.

For instance, in August 2024, Pfizer Inc has launched a new website called PfizerForAll to improve access to its healthcare offerings for migraine and respiratory illnesses. The site offers services like telehealth appointments and diagnostic tests for treatments like Paxlovid and Nurtec, as well as helping patients find vaccines for COVID, flu, RSV, and pneumonia.

Moreover, in March 2023, Pfizer has approved ZAVZPRET, the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine in adults. The study showed ZAVZPRET was statistically superior to placebo in pain freedom and freedom from most bothersome symptoms at two hours post-dose, and pain relief as early as 15 minutes compared to the placebo.

Furthermore, in April 2023, AbbVie has expanded QULIPTA (atogepant)'s indication for migraine prevention in adults, making it the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine. Chronic migraine sufferers experience 15 or more days of headaches per month, with at least eight days associated with migraine.

Europe is growing at the fastest pace in the migraine drugs market

Europe holds the fastest pace in the migraine drug market and is expected to hold most of the market share.

The migraine drugs market in Europe is expected to grow due to the significant migraine population and the approval of new treatments, well-developed healthcare infrastructure and wide range of medical services, supportive regulatory and reimbursement policies, driving new players and market growth. Also due to the rising number of aging people and increased susceptibility to migraines. As the population ages, the demand for migraine drugs is expected to increase, driving market growth. Overall, the migraine drugs market is a lucrative region for the industry. For instance, in April 2024, NHS experts are recommending atogepant, the first oral treatment for chronic and episodic migraines, to 170,000 people in England. The treatment is recommended for those who have not responded well to other medications or cannot have injections. The National Institute for Health and Care Excellence (NICE) has recommended the tablet form after clinical trials showed it was effective in some adults. The migraine charity hopes for swift access to the drug.

Competitive Landscape

The major global players in the market include Amgen Inc, Tonix Pharmaceuticals, Teva Pharmaceuticals, Eli Lilly and Company, AbbVie Inc, Pfizer Inc, Lundbeck, Impel Pharmaceuticals Inc, Currax Pharmaceuticals, Endo Pharmaceuticals Inc among others.

Emerging Players

The emerging players in the migraine drugs market include Biohaven pharmaceuticals, Axsome Therapeutics and among others.

Key Developments
• In January 2024, Lasmiditan developed by Akums Drugs and Pharmaceuticals Ltd, is a selective serotonin receptor agonist used for migraine comfort. It works by interrupting pain signals to the brain and also deals with inflammation of the nerves. The tablet contains lasmiditan hemisuccinate that conjugates with the 5-HTIF receptor offering relief from migraines. The medication has also been authorized by the Drug Controller General of India and its counterpart in the United States.
• In April 2024, The National Institute for Health and Care Excellence (NICE) has given their nod for Atogepant (Aquipta) to be used in England, for the prevention of migraine headaches. This case follows the approval of Rimegepant in all UK countries for preventing migraines, and for treatment, it has been approved in England, Scotland and Wales.

Why Purchase the Report?
• To visualize the global migraine drugs market segmentation based on drug class, route of administration, age group, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of migraine drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global migraine drugs market report would provide approximately 70 tables, 69 figures, and 202 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.